Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a...
Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
About this item
Full title
Author / Creator
Mangel, Allen and Hicks
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms of pain and altered bowel function. The kappa-opioid agonist asimadoline is being evaluated in Phase III as a potential treatment for IBS. Asimadoline, to date, has shown a good safety profile and the target Phase III population - diarrhea-predominant IBS patients...
Alternative Titles
Full title
Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3278196
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3278196
Other Identifiers
ISSN
1178-7023
E-ISSN
1178-7023
DOI
10.2147/CEG.S23274
